An audit of treatment outcome in acromegalic patients attending our center at Bergamo, Italy
- PMID: 17690987
- DOI: 10.1007/s11102-007-0059-1
An audit of treatment outcome in acromegalic patients attending our center at Bergamo, Italy
Abstract
Background: Acromegaly is a chronic disease impacting on morbidity and mortality. Increased mortality is reverted after the achievement of hormonal targets. The relative role of treatment options is still matter of debate.
Methods: A retrospective chart review was performed on all the acromegalic patients attending our center along the last 20 years.
Results: Data about 159 patients (83 F) were retrieved and analyzed: 18% had been lost to follow-up, while follow-up was >5 years in 79%. Growth hormone (GH) at diagnosis was 24 microg/L (median, range 3-239). Pituitary MRI showed a macro-, micro-adenoma or no lesion in 73.6, 22.9, and 3.5%, respectively. Hyperprolactinemia (hyperPRL) was present in 20.8%. Ninety-six and 29 patients had been treated by neurosurgery (NS) and irradiated (RT), respectively. Drugs had been employed in 149 patients (in 58 as the only treatment). At the last evaluation, 22% of patients were cured (hypopituitarism and GH deficiency in 6.3%), 37.1% were controlled by ongoing pharmacological treatment, 22.6% had discordant GH and Insulin-like growth factor I (IGF-I) values, and 18.2% had still active disease (median follow-up in this last group was 9 months). By evaluating the outcome with a multimodal approach, safe GH and normal IGF-I had been achieved in 78 and 63.5% of the whole series, 80.5 and 59.7% in patients submitted to NS (and adjuvantly treated with drugs), 95.8 and 91.7% in those submitted to NS + RT (and drugs as well), 70.2 and 55.2% in those treated only with drugs (increased to 82.2 and 60.9% if considering only patients treated with modern long-acting drugs). Hypopituitarism had occurred in 25, 66.6, and 13.8% in the three groups, respectively. At multivariate analysis, previous RT and NS were significant positive predictors of cure, whereas previous NS, follow-up, and year of diagnosis were significant positive predictors of control. Diabetes was a negative predictor both of cure and control. Sex, age, baseline GH levels, hyperPRL, tumor size, extrasellar extension, and invasiveness were not independent predictors of either cure or control.
Conclusion: This series seems to indicate that a multimodal approach can achieve control of disease in most patients.
Similar articles
-
Acromegaly.Pituitary. 2006;9(4):297-303. doi: 10.1007/s11102-006-0409-4. Pituitary. 2006. PMID: 17077948 Review.
-
[Outcome of somatostatin analogue treatment in acromegaly].Orv Hetil. 2009 Aug 2;150(31):1457-62. doi: 10.1556/OH.2009.28688. Orv Hetil. 2009. PMID: 19617182 Hungarian.
-
Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.J Clin Endocrinol Metab. 2006 Jan;91(1):85-92. doi: 10.1210/jc.2005-1208. Epub 2005 Nov 1. J Clin Endocrinol Metab. 2006. PMID: 16263832
-
Therapy for the syndromes of GH excess.J Endocrinol Invest. 2003;26(10 Suppl):36-43. J Endocrinol Invest. 2003. PMID: 15497658 Review.
-
Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.J Neurosurg. 2013 Dec;119(6):1467-77. doi: 10.3171/2013.8.JNS13224. Epub 2013 Sep 27. J Neurosurg. 2013. PMID: 24074496 Review.
Cited by
-
Surgery induced hypopituitarism in acromegalic patients: a systematic review and meta-analysis of the results.Pituitary. 2015 Dec;18(6):844-60. doi: 10.1007/s11102-015-0661-6. Pituitary. 2015. PMID: 26113357
-
Clinical characteristics and treatment outcomes in acromegaly, a retrospective single-center case series from Thailand.Pan Afr Med J. 2021 Sep 10;40:31. doi: 10.11604/pamj.2021.40.31.29920. eCollection 2021. Pan Afr Med J. 2021. PMID: 34795812 Free PMC article.
-
Acromegalic patients lost to follow-up: a pilot study.Pituitary. 2013 Jun;16(2):245-50. doi: 10.1007/s11102-012-0412-x. Pituitary. 2013. PMID: 22821645
-
Clinical features and therapeutic outcomes of patients with acromegaly: single-center experience.J Endocrinol Invest. 2011 Dec;34(11):e382-5. doi: 10.3275/7858. Epub 2011 Jul 12. J Endocrinol Invest. 2011. PMID: 21750393
-
Predictors of surgical outcome and early criteria of remission in acromegaly.Endocrine. 2018 Jun;60(3):415-422. doi: 10.1007/s12020-018-1590-8. Epub 2018 Apr 6. Endocrine. 2018. PMID: 29626274
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous